Integrated Platform Drug Discovery and Development Companies - Part 1 By Dr Urban A. Kiernan and Dr Stephen Naylor Technology was lauded as the saviour of the drug discovery and development (DDD) process during the late 1990s. A myriad of independent companies developed and offered ‘innovative’ tools, technologies and platforms… Read More
Cell Therapy - Preserving Cell Integrity and Viability To Drive Discovery Mary Kay Bates Cell therapy is poised to play a pivotal role in the development of precision and personalised medicines that will transform healthcare for millions of patients worldwide. Involving the direct use of whole cells or cellular material… Read More
Analytical Biophysical Tools To Accelerate Discovery of Therapeutic Antibodies By Dr Yasmina Noubia Abdiche The innate ability of antibodies to bind their targets with high affinity and exquisite specificity is leveraged in the discovery of therapeutic antibodies to treat a broad range of diseases including cancer, autoimmune disease and heart… Read More
Disruptive Approaches To Accelerate Drug Discovery and Development (Part 2) By Dr Anton Fliri, et al. Part 2: Emergent intelligence, a new paradigm for drug discovery. (You can read part 1 of disruptive approaches to accelerate drug discovery and development linked here.) The staggering clinical trial failure rate of experimental… Read More
Astrazeneca R&D - Improving Drug Development Productivity With Better Predictivity By Dr Menelas Pangalos & Steve Rees et al. Changing demands in global healthcare over the past 15 years have led to greater complexity and spiralling costs in drug development. The average price tag of taking a new drug from… Read More
Precision Medicine Drugs - Pleonasm or Reality? Dr Urban Kiernan and Dr Stephen Naylor The complexity and uniqueness of human metabolism and physiology in the past decade has been highlighted and dissected. Arguments have been made to suggest that our lack of understanding about human individuality has led to the… Read More
How High-Throughput CRISPR is set to Deliver Knockout Performance in Drug Discovery By Dr Paul Avery and Dr Richard Massey CRISPR-Cas9 has rapidly transformed our ability to perform targeted gene editing. While the technique has received much interest for its potential in the field of gene therapy, advances in its… Read More
Bringing Immuno-Oncology Together: How An Immunologist & Oncologist Collaborate By Dr Julia Schuler and Dr Louise Brackenbury For many years, immunology and oncology operated as separate disciplines within drug discovery. However, recent advances in immuno-oncology (IO) have demonstrated what can be achieved when the two disciplines join forces in developing… Read More
Natural Killer Cells - How NK Cell Therapy Will Transform Immunotherapy By Dr Azusa Tanaka and Dr Michael Seiler Regulatory approval of CAR-T cell therapies in 2017 placed the spotlight on immunotherapy approaches that use live cells to attack tumours – a major shift in oncology treatment and the battle… Read More
The Cancer Conundrum - Increasing Clinical Success In Early Stage Drug Discovery By Lubna Hussain This article focuses on increasing clinical success in early stage drug discovery, by implementing improved methodologies in the early phase & using primary cells and 3D culture models to enhance cancer drug discovery. The high… Read More
Disruptive Approaches To Accelerate Drug Discovery and Development (Part 1) By Ibis Sanchez- Serrano, Dr Tom Pfeifer and Dr Rathnam Chaguturu This article is part 1 of 2, and covers tools, technologies and the core model of disruptive approaches to accelerate drug discovery and development. Tesla intends to implement and… Read More
The Use of Next-Generation Sequencing in Drug Development By Keith Nangle & Mike Furness This article summarises some of the technical and regulatory challenges posed by next-generation sequencing technologies and the efforts being made to address them. Next-generation sequencing (NGS) has moved from the realm of research into those of… Read More
By Dr Simon Moore, Dr Kirsty Harper & Dr Sylwia Marshall The impact and effective routes of non-clinical safety assessment of inhaled biopharmaceuticals. With the rapid generation of biological screening data and the potential for innovative selection of compounds for screening, the importance of multivendor collaborations together with improvements in… Read More
Emerging Drug Discovery Alliance Models By Dr Swati Prasad, Mary Louise Bell & Dr Charles McOsker The current environment for early-stage drug discovery and development is fluid and the probability of success continues to be challenging. Advancing an idea from an academic or basic research setting into a therapeutic product… Read More
By Dr Jason Mellad The sequencing of the human genome in 2003 signalled the dawn of an exciting new era for genetic medicine. Yet almost 15 years later it has become clear that our genes alone cannot predict our susceptibility to most complex diseases or fully explain fundamental aspects of… Read More
Oral Peptide Therapeutics - A Holy Grail or Quixotic Quest? By Dr Paul Shields Technologies have been honed to overcome many of the challenges of administering peptide therapeutics orally, but obstacles remain before drug developers can fully realise the vast potential. Proteins and peptides are the building blocks of life… Read More